Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a note issued to investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ:CHEK opened at $1.11 on Friday. Check-Cap has a 1 year low of $1.10 and a 1 year high of $3.94. The stock’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $1.93. The company has a market cap of $6.49 million, a P/E ratio of -0.37 and a beta of 0.36.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.